Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 25, 2019 08:15 ET | Source: NuCana plc

NuCana plc Announces Withdrawal of Public Offering of ADSs

EDINBURGH, United Kingdom, Jan. 25, 2019 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company (the “Company”) focused on significantly improving treatment...
January 23, 2019 16:01 ET | Source: NuCana plc

NuCana plc Announces Proposed Public Offering of ADSs

EDINBURGH, United Kingdom, Jan. 23, 2019 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients...
November 28, 2018 16:01 ET | Source: NuCana plc

NuCana to Participate in Citi's 2018 Global Healthcare Conference

EDINBURGH, United Kingdom, Nov. 28, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients...
November 27, 2018 16:01 ET | Source: NuCana plc

NuCana Reports Third Quarter 2018 Financial Results and Provides Business Update

Favorable Data Presented at ESMO on NUC-1031 (Acelarin®) and NUC-3373 First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer Initiation of Phase III Study of Acelarin in...
November 20, 2018 07:00 ET | Source: NuCana plc

NuCana to Participate in the 2018 Evercore ISI HealthCONx Conference

EDINBURGH, United Kingdom, Nov. 20, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer...
November 07, 2018 07:00 ET | Source: NuCana plc

NuCana to Participate in the Jefferies 2018 London Healthcare Conference

EDINBURGH, United Kingdom, Nov. 07, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer...
November 01, 2018 07:00 ET | Source: NuCana plc

NuCana Announces First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer

NuTide:302 Study Will Evaluate NUC-3373 in Combination with Other Agents Typically Administered with 5-FU EDINBURGH, United Kingdom, Nov. 01, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA)...
October 22, 2018 07:00 ET | Source: NuCana plc

NuCana Presents Data from Phase I Study of NUC-3373 at ESMO 2018

Single-Agent Anti-Cancer Activity Observed in Patients with Advanced Solid Tumors NUC-3373 Demonstrates Potential Advantages Compared to 5-FU NuCana has Initiated a Phase Ib Study of NUC-3373 in...
October 21, 2018 06:54 ET | Source: NuCana plc

NuCana Reports Additional Promising Clinical Data on NUC-1031 (Acelarin®) as Front-Line Treatment of Advanced Biliary Tract Cancer at ESMO 2018

50% Objective Response Rate on Intent-to-Treat Basis Observed Phase III Study of Acelarin in Front-Line Advanced Biliary Tract Cancer Planned EDINBURGH, United Kingdom, Oct. 21, 2018 (GLOBE...
October 09, 2018 13:15 ET | Source: NuCana plc

NuCana to Present New Data from its ProTide Portfolio at the European Society for Medical Oncology (ESMO) 2018 Congress

EDINBURGH, United Kingdom, Oct. 09, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients...